For its fifth edition, the NovAliX Conference "Biophysics in Drug Discovery" will be held for the first time in the US and will take place at the Hilton Back Bay in Boston, MA.
The use of biophysical methods has become pervasive in the drug discovery process, allowing not only to identify low-affinity hits at the screening stage but also to obtain detailed information on target / ligand interactions at more advanced stages (see the review Renaud et al. 2016 Nat. Rev. Drug Discov. 15: 679-698). This is perfectly illustrated by the success of FBDD (fragment-based drug design), where the progress of biophysical techniques in terms of sensitivity, speed, and automation has been instrumental (see the review Erlanson et al. 2016 Nat. Rev. Drug Discov. 15: 605-619). Indeed FBDD is now widely adopted in both academia and the pharmaceutical industry and has lead to 2 approved drugs and more than 30 compounds being evaluated in clinical trials.
The fifth edition of the conference intends again to bring together biophysicists and medicinal chemists to improve the synergy between their disciplines in order to deliver better drugs on a shorter timeline.
This year, the Scientific Programme will include the following sessions :
And we are extremely honored that Professor Martin Karplus (Nobel Prize in Chemistry 2013) has agreed to give the Keynote Lecture.
The Scientific Programme will be completed by short Exhibitor Presentations, a Poster Session and a Commercial Exhibition.